

Leukocare Strengthens Intellectual Property Portfolio on Virus Formulations in the US

Martinsried/Munich, 08 September 2021

Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, announced today that the company was granted US patent 11,060,068, which substantially strengthens Leukocare's intellectual property on virus formulations in the United States. The US patent office grants the application for a method of stabilizing viruses or bacteria in liquid, sugar-free formulations comprising three amino acids from at least three different groups.

Michael Scholl, CEO of Leukocare, said, "We are delighted that the US patent office granted this application. It clearly positions Leukocare as the global leader in biopharmaceutical formulation development, especially in the area of liquid virus formulations. This patent grant demonstrates yet again that Leukocare provides excellent formulation development technologies based on vast scientific expertise in combination with best-in-class virus analytics. Moreover, it supports our regional expansion by granting IP protection in the territory of the United States."

Leukocare holds a strong IP portfolio of patent families in its three core areas, namely virus & viral vectors, biologics & biosimilars as well as sterilization & biofunctionalized devices. With the recent opening of its US-subsiidiary in Milford, Massachusetts, Leukocare is expanding its highly successful formulation business also in the US.

About Leukocare AG

Leukocare AG, located in Martinsried/Munich, Germany and Milford, MA, USA, is a biotechnology company specialized in the field of biopharmaceutical formulation development. Operating at the interface of drug substance and drug product development, Leukocare combines sound knowledge of formulation development with bioinformatics and artificial intelligence.

The formulation development approach consists of two elements: a library of up to 100 different regulatory well-established and employed excipients and a rational development approach which employs statistical software and self-learning algorithms as well as state of the art design of experiment (DoE) matrices. By utilizing the artificial intelligence elements, Leukocare is able to specifically combine excipients leading to stabilizing formulations tailored to the drug product's needs.

Leukocare's superior and innovative drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.

www.leukocare.com

Contact:

Leukocare AG

Rebekka Ströver

Specialist Communications & Marketing

rebekka.stroeever@leukocare.com

+ 49 (0) 89 7801 665 14